阿里皮普拉/塞特拉林组合:临床效果和成本效益与治疗双极性抑郁症的奎蒂亚平相比 (ASCEnD试验) - - 嵌套定性研究协议
Isobel Hoppe1, Stuart Watson2,3, Caroline Kemp4
1School of Medicine, Keele University, Newcastle, UK.
概括
该ASCEnD试验调查是否阿里皮普拉/塞特拉林在治疗双极性抑郁症方面比奎胺更有效. 一项定性研究探讨了患者和临床医生的双相情感障碍治疗经验.
科学领域:
- 精神病学和心理健康 精神病学和心理健康
- 临床试验 临床试验
- 药理学 药理学是指药理学的学科.
背景情况:
- 双极性障碍影响1.4%的人口,往往有9.5年的显著诊断延迟.
- 双相情感障碍患者的预期寿命减少,对抗抑郁药的有效性证据有限.
- 该ASCEnD试验解决了对双相抑郁症有效治疗的需求,这是该疾病的常见和衰弱方面.
研究的目的:
- 评估阿里皮普拉/塞特拉林组合与双极性抑郁症治疗中的奎平相比的临床和成本效益.
- 探索患者和临床医生的治疗可接受性,招募和双相情感障碍管理方面的观点.
- 为了告知招聘策略,并优化为完整的ASCEnD试验培训.
主要方法:
- 该ASCEnD试验是一项比较有效性研究,测试阿里皮普拉/塞特拉林与奎平的对比.
- 嵌套定性研究采用与参与者和临床医生进行半结构面试.
- 实践经验咨询小组 (LEAP) 在整个试验设计和交付过程中提供患者的意见.
主要成果:
- 该研究正在进行中;结果将为主要试验的招聘和培训提供信息.
- 定性发现将揭示双相情感障碍的经验和对治疗的态度.
- 数据将探讨诊断延迟和患有双相情感障碍的生活影响的观点.
结论:
- 该ASCEnD试验旨在提供关于阿里皮普拉/塞特拉林治疗双极性抑郁症的有效性的关键证据.
- 了解患者和临床医生的经验对于优化治疗和试验交付至关重要.
- 这些发现将有助于改善双相情感障碍患者的管理和支持.
相关概念视频
01:23Antidepressant Drugs: MAOIs and Other Agents
205
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
205
01:26Psychosis: Goals of Pharmacotherapy
113
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
113
01:24Mania and Antimanic Drugs: Overview
155
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
155
01:28Drug Therapy
40
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
40
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
335
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
335
01:28Psychosis and Antipsychotic Drugs: Overview
203
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
203